PL450121A1 - Kompozycja farmaceutyczna - Google Patents

Kompozycja farmaceutyczna

Info

Publication number
PL450121A1
PL450121A1 PL450121A PL45012124A PL450121A1 PL 450121 A1 PL450121 A1 PL 450121A1 PL 450121 A PL450121 A PL 450121A PL 45012124 A PL45012124 A PL 45012124A PL 450121 A1 PL450121 A1 PL 450121A1
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
anhydrous
linagliptin
glidant
disintegrants
Prior art date
Application number
PL450121A
Other languages
English (en)
Inventor
Anna Krause
Hanna Kierońska
Katarzyna Rogut
Michał Kretkiewicz
Original Assignee
Pikralida Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pikralida Spółka Z Ograniczoną Odpowiedzialnością filed Critical Pikralida Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL450121A priority Critical patent/PL450121A1/pl
Publication of PL450121A1 publication Critical patent/PL450121A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest kompozycja farmaceutyczna z amorficzną substancją czynną linagliptyną, która zawiera substancję wypełniającą - laktozę bezwodną, substancje rozsadzające w układzie musującym - kwas cytrynowy bezwodny oraz wodorowęglan sodu, substancję poślizgową - krzemu dwutlenek koloidalny oraz substancję smarującą - stearynian magnezu.
PL450121A 2024-10-23 2024-10-23 Kompozycja farmaceutyczna PL450121A1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL450121A PL450121A1 (pl) 2024-10-23 2024-10-23 Kompozycja farmaceutyczna

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL450121A PL450121A1 (pl) 2024-10-23 2024-10-23 Kompozycja farmaceutyczna

Publications (1)

Publication Number Publication Date
PL450121A1 true PL450121A1 (pl) 2026-04-27

Family

ID=99547548

Family Applications (1)

Application Number Title Priority Date Filing Date
PL450121A PL450121A1 (pl) 2024-10-23 2024-10-23 Kompozycja farmaceutyczna

Country Status (1)

Country Link
PL (1) PL450121A1 (pl)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193528A1 (en) * 2013-04-29 2014-12-04 Anovel Pharmaceuticals, Llc Amorphous dosage forms and methods
EP2853257A1 (en) * 2013-09-12 2015-04-01 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical formulations of linagliptin
CN109078186A (zh) * 2017-06-14 2018-12-25 江苏恒瑞医药股份有限公司 一种胃漂浮组合物及其制备方法
CN116999440A (zh) * 2022-04-29 2023-11-07 扬子江药业集团上海海尼药业有限公司 包含利格列汀的药物组合物、药物制剂、单位剂型及制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193528A1 (en) * 2013-04-29 2014-12-04 Anovel Pharmaceuticals, Llc Amorphous dosage forms and methods
EP2853257A1 (en) * 2013-09-12 2015-04-01 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical formulations of linagliptin
CN109078186A (zh) * 2017-06-14 2018-12-25 江苏恒瑞医药股份有限公司 一种胃漂浮组合物及其制备方法
CN116999440A (zh) * 2022-04-29 2023-11-07 扬子江药业集团上海海尼药业有限公司 包含利格列汀的药物组合物、药物制剂、单位剂型及制备方法

Similar Documents

Publication Publication Date Title
NO20004721L (no) Bruseformuleringer
DK1792610T3 (da) Terapeutiske bioadhæsive systemet med langvarig frigivelse
NO20071711L (no) Sammensetninger inneholdende piperacillin, tazobactam og en aminokarboksylsyre i et natriumlaktat fortynningsmiddel
DE502005008880D1 (de) Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
ATE347879T1 (de) Transdermale pharmazeutische zusammensetzung zur wirkstoffverabreichung
AR047949A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor de factor de crecimiento endotelial
DK1191926T3 (da) Ny omeprazol- og (S)-omeprazolformulering
PY0206703A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
AR056538A1 (es) Formulacion acuosa hfsh
ATA2332000A (de) Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
DE69906963D1 (de) Efavirenz enthaltende gepresste tablettenformulierug
PL450121A1 (pl) Kompozycja farmaceutyczna
CR20250293A (es) Formulaciones de enzima hialuronidasa para la administración de alto volumen
AR123691A1 (es) Formulaciones farmacéuticas
PT1414467E (pt) Tratamento topico da mastalgia
MX2024010155A (es) Formulacion combinada de cedazuridina
FR2666508B1 (fr) Compositions pharmaceutiques contenant des derives de furanne.
HRP20050342B1 (hr) Farmaceutska formulacija olanzapina
EA202092077A1 (ru) Местные составы, содержащие стронций и метилсульфонилметан (мсм), и способы лечения
UY27373A1 (es) Formulaciones de interferón beta-humano
CA2550157A1 (en) Compositions and methods for modulating sirtuin activity
AR027287A1 (es) Gonadotrofina
NO20052960L (no) Anvendelse av dokosahekasensyre som aktivt stoff til behandling av lipodystrofi
PL449748A1 (pl) Liofilizat z owoców derenia jadalnego Cornus mas L. do zastosowania w zapobieganiu hipoksji
ATE203903T1 (de) Delta-aminolävulinsäure enthaltendes arzneimittel